PATIENTS
PATIENTS
Clinical Trials
Our clinical trials help to advance the understanding of innovative medicines and determine whether the new treatments being developed are safe and effective.
We know that the decision to participate in clinical trial research is not made lightly, and we sincerely thank all the patients and families who choose to participate. Your physician is the best person to help you decide if a clinical trial or any other treatment option is right for you.
The potential treatments listed below are currently under investigation. Their safety and effectiveness have not been established. An investigational drug must be proven safe and effective in clinical trials before it can be approved by the health authorities for prescription use or for use outside of an investigational research study.
Learn more about clinical trials and how they work.
About PROTAC Protein Degraders:
Proteins are molecules that carry out important processes in our cells. However, sometimes certain proteins become damaged or too abundant, which can lead to disease. One of the ways the body naturally targets and eliminates harmful proteins is through the ubiquitin-proteasome system, or UPS. Arvinas is developing a way to make use of this process to destroy disease-causing proteins, called PROTACs. PROTACs have the potential to make use of the body’s natural disposal system to break down proteins that cause different diseases and are currently being studied in clinical trials.
The agents listed below are currently under investigation. Their safety and effectiveness have not been established.
ARV-393 is an investigational oral medicine which is a PROTAC designed to specifically target and degrade a protein called B-cell lymphoma 6 (BCL6) that is present in many types of non-Hodgkin’s lymphomas and can become damaged or too abundant and promote the growth of certain types of cancer. ARV-393 is currently undergoing clinical trials to determine how well it works and how safe it is for treating non-Hodgkin’s lymphomas.
Currently Enrolling:
- A Phase 1 First-in-Human study of ARV-393 is being conducted on adult participants diagnosed with advanced Non-Hodgkin’s Lymphoma (NHL) (NCT06393738). This clinical trial aims to investigate the safety, and potential activity of the investigational drug ARV-393 in patients with advanced relapsed/refractory non-Hodgkin’s lymphoma.
If you are interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact us at +1-475-345-3374 or via email at clinicaltrialsARV-393@arvinas.com.
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.
ARV-806 is an investigational PROTAC designed to bind to and degrade both the active and inactive forms of KRAS G12D. Kirsten rat sarcoma (KRAS) has historically been considered an “undruggable” target due to its lack of deep “pockets” and is associated with poor prognosis and resistance to standards of care in several tumor types.
Currently Enrolling:
- A Study to evaluate ARV-806 in adults with advanced cancer that has the KRAS G12D mutation (NCT07023731). This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in adults with advanced cancer having a specific KRAS mutation. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-806.
If you are interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact us at +1-475-345-3374 or via email at clinicaltrialsARV-393@arvinas.com.
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.
Vepdegestrant is an investigational oral medicine which is a PROTAC designed to specifically target and degrade the estrogen receptor (ER). Estrogen receptors are proteins that can help promote the growth of certain types of cancer, including breast cancer.
Vepdegestrant is currently undergoing clinical trials to determine how well it works and how safe it is for treating ER-positive/HER2-negative breast cancer.
Vepdegestrant is believed to work by eliminating estrogen receptors, blocking estrogen activity, and potentially stopping tumor growth or causing shrinkage.
Currently Enrolling:
- Vepdegestrant in combination with PF-07248144 (NCT04606446)
- This clinical trial aims to evaluate safety and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents, one of which is vepdegestrant. This study is being run by Pfizer.
If you are interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact Pfizer at 1-800-718-1021 or via email at ClinicalTrials.gov_Inquiries@pfizer.com.
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.
Luxdegalutamide is an investigational oral PROTAC designed to specifically target and degrade the androgen receptor (AR), a protein that plays a key role in driving the growth of prostate cancer. In April 2024, Arvinas entered into a global license agreement with Novartis for the development and commercialization of luxdegalutamide for the treatment of prostate cancer. The deal also includes the sale of the AR-V7 program to Novartis. Learn more.